Nuwellis Inc
$ 1.49
-8.59%
07 Aug - close price
- Market Cap 150,290 USD
- Current Price $ 1.49
- High / Low $ 1.63 / 1.46
- Stock P/E 0.03
- Book Value 35.34
- EPS 47.25
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.13 %
- ROE -6.09 %
- 52 Week High 235.20
- 52 Week Low 1.34
About
Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.
Analyst Target Price
$11.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-10 | 2025-11-12 | 2025-08-14 | 2025-05-13 | 2025-03-11 | 2024-11-11 | 2024-08-13 | 2024-05-07 | 2024-03-05 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -73.15 | -1.5 | 19.6 | -2134.65 | -1014.3 | -0.44 | 2557.81 | -27709.56 | -0.6 | -115248.35 | -93124.78 | -187793.06 |
| Estimated EPS | -35 | -1.56 | -602.7 | -661.5 | -661.5 | -0.43 | -1881.6 | -12120.18 | -1.06 | -71515.71 | -160181.48 | -207001.12 |
| Surprise | -38.15 | 0.06 | 622.3 | -1473.15 | -352.8 | -0.01 | 4439.41 | -15589.38 | 0.46 | -43732.64 | 67056.7 | 19208.06 |
| Surprise Percentage | -109% | 3.8462% | 103.252% | -222.6984% | -53.3333% | -2.3256% | 235.938% | -128.6233% | 43.3962% | -61.1511% | 41.863% | 9.2792% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NUWE
2026-08-06 23:09:38
Nuwellis, Inc. (NASDAQ:NUWE) has appointed Dale Brady as Principal R&D Engineer. Brady brings over 25 years of medical device experience in R&D, operations, manufacturing, quality systems, and commercialization, and will focus on new and existing product development programs. He has a strong background, including leadership roles at Peytant Solutions, Endogenex, Osprey Medical, Anulex Technologies, and Spine-Tech, and is an inventor on numerous patents.
2026-08-06 21:41:38
A group consisting of Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC has reported a 4.7% beneficial ownership stake in Nuwellis, Inc. (NUWE) through warrants. The ownership, totaling 155,536 common shares, is largely derived from warrants associated with a Securities Purchase Agreement dated July 31, 2026, and is subject to a 4.99% ownership blocker provision. This disclosure was made via a SCHEDULE 13G filing, indicating shared voting and dispositive power over the shares by the reporting persons.
2026-08-06 12:41:38
Nuwellis, Inc. has appointed Dale Brady as Principal R&D Engineer to bolster its product development organization. Brady brings over 25 years of medical device engineering experience, including leading multidisciplinary teams and developing products from concept to commercialization. His expertise is expected to accelerate innovation and strategic initiatives for Nuwellis' cardiorenal solutions.
2026-08-06 12:41:27
Nuwellis (Nasdaq: NUWE) has appointed Dale Brady as Principal R&D Engineer, leveraging his extensive 25 years of experience in medical device development and commercialization. Brady will contribute his expertise to advance Nuwellis' existing and new product development programs for cardiorenal solutions. This appointment is expected to strengthen the company's product development organization and accelerate innovation.
2026-08-06 12:41:27
Nuwellis, Inc. has announced the appointment of Dale Brady as Principal R&D Engineer. Brady brings over 25 years of experience in medical device research and development, operations, manufacturing, quality systems, and commercialization. He will lead internal product development initiatives for the company, which specializes in solutions for patients with cardiorenal conditions.
2026-08-05 21:42:09
Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton have reported a 6.2% beneficial ownership stake in Nuwellis, Inc. (NUWE) through shares and capped warrants. The stake includes 193,050 shares of common stock and an equal number of warrants, with a provision limiting conversions that would cause ownership above 4.99%. Each reporting person has sole voting and dispositive power over these shares, as detailed in the SCHEDULE 13G filing.
